Immunic Presents New Vidofludimus Calcium Data at MSToronto2026; OLE Disability Trends Favor Continuous Treatment

What happened

Immunic announced four abstracts accepted at MSToronto2026 featuring new clinical, biomarker, and preclinical data on vidofludimus calcium. Notable among these are new Phase 2 CALLIPER open-label extension (OLE) data showing disability outcomes favoring continuous treatment through week 48, with low discontinuation. These data come after the CALLIPER primary endpoint (brain atrophy) was missed in the double-blind phase, tempering the neuroprotection thesis. The company remains in a precarious financial position with ~$55.3M cash as of June 30, 2025, and management has disclosed going-concern uncertainty. The positive OLE trends may help rebuild confidence in the drug's disease-modifying potential, but pivotal Phase 3 ENSURE results are still needed to confirm benefit.

Implication

For investors, the OLE disability trends are encouraging and may reduce some skepticism around vidofludimus calcium's ability to slow progression, but the primary endpoint miss in the double-blind phase remains a concern. The presentation of biomarker and preclinical data, including Nurr1-mediated neuronal survival and EBV-related immune activity, could strengthen the mechanistic case, but these are not substitutes for hard clinical endpoints. With top-line ENSURE data expected by end-2026, the stock will likely remain range-bound until those results, and the immediate focus should be on how the company addresses its cash runway. If the company can secure non-dilutive financing or a partnership that funds operations through the data readout, the risk/reward improves; otherwise, a dilutive raise or worse remains a threat. Overall, the news supports a neutral-to-slightly-positive shift in sentiment, but we maintain a HOLD stance pending more definitive clinical and financial clarity.

Thesis delta

No major change to our investment thesis. The OLE data are supportive but not pivotal, echoing earlier positive biomarker trends. Our stance remains NEUTRAL/HOLD with a bias to accumulate only if financing is secured and ENSURE holds promise.